Cirius Eyes Phase III Plans In NASH With Interim Data Showing Liver, Metabolic Benefits

Phase IIb interim look shows liver enzyme reductions, signs of glycemic control and no increase in peripheral edema from baseline. Cirius expects to have final data in the second half of 2019.

scientists doing lab research on digital screen

The non-alcoholic steatohepatitis (NASH) clinical development field is crowded with various players, targets and therapeutic approaches, but privately held Cirius Therapeutics Inc. thinks it may have a winner as its second-generation thiazolidinedione MSDC-0602K has shown ability to reduce liver enzymes and improve glycemic control with a good safety profile in a Phase IIb interim look.

Designed by Cirius co-founder and Vice President-R&D Jerry Colca to offer the insulin-sensitizing benefits of first-generation TZDs like Takeda...

More from Alimentary/Metabolic

More from Therapeutic Category